Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. 10-K, Item 1

Headquarters
Rockville, MD
CEO
Jack A. Khattar
Next results
around Feb 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2024

Revenue of $661.8M through the costs to a net profit of $73.9M · income statement of the 10-K

12% operating margin
Revenue to Gross profit: $583.9MRevenue to Cost of revenue: $77.9MGross profit to Operating profit: $81.7MGross profit to Operating expenses: $502.2MOperating profit to Net profit: $57.7MOperating profit to Tax: $24.0MOther income to Net profit: $16.2MOperating expenses to R&D: $108.8MOperating expenses to Sales, admin & other: $393.4M Revenue: $661.8M REVENUE $661.8M +9% Y/Y Gross profit: $583.9M · 88% margin GROSS PROFIT $583.9M 88% margin Cost of revenue: $77.9M · 12% of revenue COST OF REVENUE $77.9M 12% of revenue Operating profit: $81.7M · 12% margin OPERATING PROFIT $81.7M 12% margin Other income: $16.2M · 2% of revenue OTHER INCOME $16.2M 2% of revenue Operating expenses: $502.2M · 76% of revenue OPERATING EXPENSES $502.2M 76% of revenue Net profit: $73.9M · 11% margin NET PROFIT $73.9M 11% margin · +5513% Y/Y Tax: $24.0M · 4% of revenue TAX $24.0M 4% of revenue R&D: $108.8M · 16% of revenue R&D $108.8M 16% of revenue Sales, admin & other: $393.4M · 59% of revenue SALES, ADMIN & OTHER $393.4M 59% of revenue
Gross profit $583.9M 88% margin
Operating profit $81.7M 12% margin
Net profit $73.9M 11% margin · +5513% Y/Y
The full income statement, year by year

SUPN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 8.6%, above 44% of 154 peers (their median 10.5%) REVENUE GROWTH 8.6% · above 44% Gross margin: 87.6%, above 93% of 107 peers (their median 63.4%) GROSS MARGIN 87.6% · above 93% Operating margin: -5.7%, above 22% of 138 peers (their median 10.2%) OPERATING MARGIN -5.7% · above 22% Net margin: -5.1%, above 24% of 153 peers (their median 6.8%) NET MARGIN -5.1% · above 24% FCF margin: 10.1%, above 51% of 144 peers (their median 9.9%) FCF MARGIN 10.1% · above 51%
SUPN Peer median Below the median

What changed

34 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Mar 2, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +32.2% ($142.1M to $187.8M) vs revenue +8.6% ($661.8M to $719.0M), +23.6 pts apart
  • Inventory growing faster than revenue
    Inventory +107.2% ($54.3M to $112.5M) vs revenue +8.6% ($661.8M to $719.0M), +98.5 pts apart
  • Cash from operations $47.3M vs net income −$38.5M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Accrued sales deductions related to product returns
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

34 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 34 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Third parties have developed, received FDA approval and successfully commercialized longer-lasting extended relief levodopa/carbidopa products, which are impacting sales of APOKYN because they reduce the number of times per day a given patient may need to use an off-episode product like APOKYN. Third parties have also developed,…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    The commercial results of ZURZUVAE® (zuranolone) depend, in part, on our ability, with our collaboration partner, Biogen MA Inc., and Biogen International GmbH, or together, Biogen, to successfully continue the commercialization of the product for the treatment of women with postpartum depression, or PPD, in the U.S. There is no…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    During 2025 several Executive Orders were issued by the President of the United States, which generally aim to lower the price paid for certain pharmaceutical products in the United States. Aspects of these orders direct the Secretary of Health and Human Services to develop implementation plans and to issue related regulations. We are…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    The U.S. and certain states have shown significant, increased interest in pursuing healthcare reform and changes to the healthcare delivery system. Numerous major markets outside the U.S., including the EU, Japan, and China, have widespread governmental involvement in healthcare funding, including with regard to pricing and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$667.2M$607.5M$661.8M$719.0M
Net income$60.7M$1.3M$73.9M−$38.5M
Operating cash flow$116.8M$111.1M$172.0M$47.3M
Free cash flow$116.4M$110.5M$171.2M$46.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$719.0M ▲ 8.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

10 filings in the last 30 days · SEC EDGAR

All filings
5 more

About the company

Supernus, Inc., Rockville, MD · from the 10-K filed Mar 2, 2026

Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.

Headquarters
Rockville, MD
Country
United States
Reports in
USD
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Mar 2, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.